专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2698637A1 Marker for determination of sensitivity to anti-cancer agent 有权
标题翻译： Marker zur Bestimmung der Empfindlichkeitfürein Antikrebsmittel
公开(公告)号：EP2698637A1
公开(公告)日：2014-02-19
申请号：EP13005363.0
申请日：2009-01-30
申请人： Keio University , KABUSHIKI KAISHA YAKULT HONSHA
发明人： Tanigawara, Yusuke , Watanabe, Mitsuhiro , Arita, Eri , Nishimuta, Akito , Yamayoshi, Yasuko , Matsuzaki, Takeshi , Sugimoto, Shinji
IPC分类号： G01N33/68 , A61K31/4745 , A61K45/00 , A61P35/00 , G01N27/447 , G01N27/62 , G01N33/15 , G01N33/50
CPC分类号： A61K31/4745 , A61K45/06 , G01N33/5011 , G01N33/6812 , G01N2800/52 , Y10S436/813 , A61K2300/00
摘要： Provided are a marker for determining sensitivity to an anticancer agent capable of distinguishing a therapeutic response of an individual patient and a novel means for a cancer therapy using the marker. The marker for determining sensitivity to an anticancer agent contains a substance in a metabolic pathway in which L-phenylalanine and/or N,N-dimethyl glycine are/is involved.
摘要翻译：提供了用于确定对能够区分个体患者的治疗反应的抗癌剂的敏感性的标记和使用该标记的癌症治疗的新手段。用于确定对抗癌剂的敏感性的标记物含有涉及L-苯丙氨酸和/或N，N-二甲基甘氨酸的代谢途径中的物质。

2. 发明公开

EP2495568A1 Method for determining sensitivity to an anticancer agent 有权
标题翻译：确定对抗癌剂敏感性的方法
公开(公告)号：EP2495568A1
公开(公告)日：2012-09-05
申请号：EP10826878.0
申请日：2010-10-29
申请人： Keio University , Kabushiki Kaisha Yakult Honsha
发明人： Tanigawara, Yusuke , Suzuki, Sayo , Irie, Hidehiro , Nishimuta, Akito , Suzuki, Tetsuya , Sugimoto, Shinji
IPC分类号： G01N33/68 , A61K31/4745 , A61K31/513 , A61K45/06 , A61P35/00 , A61P43/00 , G01N27/62 , G01N33/15 , G01N33/50
CPC分类号： G01N33/574 , A61K31/4745 , A61K31/513 , A61K45/06 , G01N2800/52 , A61K2300/00
摘要： To provide a marker for determining sensitivity of a patient to an anti-cancer agent, and novel cancer therapeutic means employing the marker.
The marker for determining sensitivity to an anti-cancer agent is formed of a protein selected from the group consisting of a protein or a fragment thereof which is detected as a peak at m/z of 16,450 to 16,620, a protein or a fragment thereof which is detected as a peak at m/z of 22,080 to 22,310, and a protein or a fragment thereof which is detected as a peak at m/z of 17,100 to 17,270, the peaks being determined by means of a mass spectrometer.
摘要翻译：为了提供用于确定患者对抗癌剂的敏感性的标记，以及采用该标记的新型癌症治疗手段。用于测定对抗癌剂的敏感性的标志物由选自下列的蛋白质形成：作为m / z为16,450至16,620的峰检测的蛋白质或其片段，其蛋白质或其片段，其蛋白质或其片段被检测为m / z为22,080至22,310的峰，以及在17,100至17,270的m / z处被检测为峰的蛋白质或其片段，所述峰通过质谱仪测定。

3. 发明授权

EP2495568B1 Method for determining sensitivity to an anticancer agent 有权
公开(公告)号：EP2495568B1
公开(公告)日：2018-08-22
申请号：EP10826878.0
申请日：2010-10-29
申请人： Keio University , Kabushiki Kaisha Yakult Honsha
发明人： Tanigawara, Yusuke , Suzuki, Sayo , Irie, Hidehiro , Nishimuta, Akito , Suzuki, Tetsuya , Sugimoto, Shinji
IPC分类号： A61K31/4745 , A61K31/513 , A61K45/06 , G01N33/574
CPC分类号： G01N33/574 , A61K31/4745 , A61K31/513 , A61K45/06 , G01N2800/52 , A61K2300/00
摘要： To provide a marker for determining sensitivity of a patient to an anti-cancer agent, and novel cancer therapeutic means employing the marker. The marker for determining sensitivity to an anti-cancer agent is formed of a protein selected from the group consisting of a protein or a fragment thereof which is detected as a peak at m/z of 16,450 to 16,620, a protein or a fragment thereof which is detected as a peak at m/z of 22,080 to 22,310, and a protein or a fragment thereof which is detected as a peak at m/z of 17,100 to 17,270, the peaks being determined by means of a mass spectrometer.

4. 发明授权

EP2698637B1 Marker for determination of sensitivity to anti-cancer agent 有权
标题翻译：感受性判定标记，对抗癌剂
公开(公告)号：EP2698637B1
公开(公告)日：2015-08-12
申请号：EP13005363.0
申请日：2009-01-30
申请人： Keio University , KABUSHIKI KAISHA YAKULT HONSHA
发明人： Tanigawara, Yusuke , Watanabe, Mitsuhiro , Arita, Eri , Nishimuta, Akito , Yamayoshi, Yasuko , Matsuzaki, Takeshi , Sugimoto, Shinji
IPC分类号： G01N33/68 , A61K31/4745 , A61K45/00 , A61P35/00 , G01N27/447 , G01N27/62 , G01N33/15 , G01N33/50
CPC分类号： A61K31/4745 , A61K45/06 , G01N33/5011 , G01N33/6812 , G01N2800/52 , Y10S436/813 , A61K2300/00

5. 发明公开

EP2302077A1 PSMB9 is a marker of immunological tolerance and transplant rejection 审中-公开
标题翻译： PSMB9 ist ein Marker von immunologischer Toleranz und Transplantsabstossung
公开(公告)号：EP2302077A1
公开(公告)日：2011-03-30
申请号：EP10182282.3
申请日：2005-05-30
申请人： Keio University
发明人： Tanigawara, Yusuke , Iketani, Osamu , Mihara, Kiyoshi
IPC分类号： C12Q1/68 , C12N15/09 , G01N33/50
CPC分类号： C12Q1/6876 , C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , G01N33/68 , G01N2333/4703 , G01N2333/82 , G01N2333/96466 , G01N2800/245
摘要： [PROBLEMS]
To provide a gene marker which enables diagnosis of rejection, evaluation of the efficacy of an immunosuppressive agent, and determination of the presence or absence of immunological tolerance; methods that can be performed in a quick, simple, and convenient manner by using a gene marker as an indicator for diagnosing rejection, evaluating the efficacy of an immunosuppressive agent, identifying an immunosuppressive agent, selecting an immunosuppressive agent, determining the dose of an immunosuppressive agent, and judging the presence or absence of immunological tolerance; and a kit.
[MEANS FOR SOLVING PROBLEMS]
Immune-related genes whose expression levels were increased by 1.5-fold or more because of rejection and whose expression levels were decreased by 1.5-fold or more because of immunosuppressive agents have been identified as gene markers. By using the expression level of one of these gene markers as an indicator, it becomes possible to diagnose rejection, evaluate the efficacy of an immunosuppressive agent, and judge the presence or absence of immunological tolerance in a quick, simple, and convenient manner.
摘要翻译： [问题]提供能够诊断排斥，评估免疫抑制剂的功效和测定有无免疫耐受性的基因标记物。可以通过使用基因标记物作为诊断排斥反应的指标，评估免疫抑制剂的功效，鉴定免疫抑制剂，选择免疫抑制剂，确定免疫抑制剂的剂量的方法，可以以快速，简单和方便的方式进行代理，判断是否存在免疫耐受; 和一个工具包。用于解决问题的手段由于排斥，其表达水平由于免疫抑制剂而降低了1.5倍以上的免疫相关基因已经被鉴定为基因标记。通过使用这些基因标记之一的表达水平作为指标，可以诊断排斥反应，评价免疫抑制剂的功效，并以快速，简单和方便的方式判断免疫耐受性的有无。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式